A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with docetaxel.

Phase 1

OncoMed Pharmaceuticals, Inc.

Docetaxel